Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Last updated: October 31, 2022
Sponsor: University of California, Los Angeles
Overall Status: Active - Recruiting

Phase

N/A

Condition

Glaucoma

Dry Eye Disease

Dry Eyes

Treatment

N/A

Clinical Study ID

NCT04354545
19-000843
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Currently using one or more topical glaucoma antihypertensives
  • Self-described symptoms of ocular surface discomfort
  • Xiidra is being prescribed as part of the subject's standard care

Exclusion

Exclusion Criteria:

  • History of glaucoma filtration surgery, history of ocular surface surgery (pterygium,conjunctivoplasty, etc.),
  • current use of topical cyclosporine
  • current use of topical steroids
  • incisional ocular surgery within 6 months

Study Design

Total Participants: 75
Study Start date:
April 01, 2021
Estimated Completion Date:
June 01, 2024

Study Description

To assess glaucoma patients' response to treatment with Xiidra (Lifitegrast ophthalmic solution) 5% for ocular surface discomfort caused, in part, by topical glaucoma antihypertensive medications.

Connect with a study center

  • Doheny Eye Center UCLA

    Fountain Valley, California 92708
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.